Crescent Biopharma to Present at Jefferies London Healthcare Conference 2024
Crescent Biopharma has announced its upcoming presentation at the Jefferies London Healthcare Conference on November 19, 2024, at 12:30 pm GMT/7:30 am EDT.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Crescent Biopharma has announced its upcoming presentation at the Jefferies London Healthcare Conference on November 19, 2024, at 12:30 pm GMT/7:30 am EDT. The company will showcase its lead program CR-001, a tetravalent VEGF1 x PD-1 bispecific antibody being developed for solid tumor treatment.
The presentation will be available via live webcast, with a recording accessible for 90 days afterward. This announcement follows Crescent's recent acquisition agreement with GlycoMimetics (NASDAQ: GLYC) in October 2024. Post-merger, the combined entity will operate as Crescent, focusing on advancing precision-engineered biologics for solid tumor treatments.
Details
News Market Reaction – GLYC
The recorded move for GLYC in the trading session of this news was -5.29%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Company to highlight lead program CR-001, a tetravalent VEGF1 x PD-1 bispecific antibody in development for treating solid tumors
A live webcast of the presentation will be available at https://wsw.com/webcast/jeff315/cresc/1987776. An archived recording will be available for 90 days following the event.
In late October, Crescent entered into an acquisition agreement with
About Crescent Biopharma
Crescent Biopharma is a biotechnology company dedicated to advancing novel precision engineered molecules targeting validated biology to advance care for patients with solid tumors. The company's pipeline of three programs harnesses proven biology to accelerate the path to market for potentially best-in-class therapeutics. For more information, visit www.crescentbiopharma.com.
Media Contact:
Deerfield Group
Lia Dangelico
540-303-0180
lia.dangelico@deerfieldgroup.com
Investor Contact:
Argot Partners
Dawn Schottlandt
212-600-1902
dawn@argotpartners.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/crescent-biopharma-to-present-at-jefferies-london-healthcare-conference-2024-302301827.html
SOURCE Crescent Biopharma
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.